Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal doxorubicin and cisplatin in malignant pleural mesothelioma
NCT00886028Phase 2Unknown
- Sponsor
- Instituto Nacional de Cancerología
- Start
- Sep 2006
- Primary completion
- Apr 2009
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegylated liposomal doxorubicin in malignant pleural mesothelioma (MPM), sponsored by Instituto Nacional de Cancerología. Primary endpoints: Progression-Free Survival at 12 months and Overall Survival at 12 months. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00886028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00886028.